A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

This publication has 37 references indexed in Scilit:

• Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis
  Critical Reviews in Oncology/Hematology, 2012
• Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
  Annals of Oncology, 2011
• Detecting Disabilities in Older Patients With Cancer: Comparison Between Comprehensive Geriatric Assessment and Vulnerable Elders Survey-13
  Journal of Clinical Oncology, 2010
• EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population
  Annals of Oncology, 2009
• Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
  Journal of Clinical Oncology, 2008
• First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
  British Journal of Cancer, 2008
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale
  Cancer, 1994
• A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  Journal of Chronic Diseases, 1987
• Measuring the quality of life of cancer patients
  Journal of Chronic Diseases, 1981